


ETCTN Trials by Disease/ Treatment Area: Head and Neck/Thyroid Cancer



NOTE: * No ClinicalTrials.gov webpage is available currently (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide

ETCTN Head/Neck and Thyroid Cancer Trials (Open as of 9/8/2025)

Protocol Number	Phase	Protocol Title
10492	I/Ib	Phase I/Ib Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer
10553	II	A Phase II Clinical and Biomarker Study of Darolutamide in Combination with Androgen Deprivation Therapy (ADT) for Hormone-Therapy Naïve Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer Patients
10706	I/II	A Phase 2 Window of Opportunity Trial of Neoadjuvant Agonistic Anti-CD40 Antibody CDX-1140 and Cemiplimab in AJCC Stage III-IV Head and Neck Cancer Patients Prior to Surgery
10721	II	Neoadjuvant Chemotherapy with or without Cemiplimab (REGN2810) in Sinonasal Squamous Cell Carcinoma: A Randomized Phase 2 Study
10732	I	Phase I Trial of ATR Inhibitor Camonsertib Combined with Stereotactic Body Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
10731	II	Phase 2 Trial of IMC-F106C (Brenetafusp) in Unresectable, Recurrent or Metastatic Adenoid Cystic Cancer